Genetic-guided Risk Assessment and Management of Thyroid Cancer

Mingzhao Xing

doi:10.1016/j.ecl.2018.11.007

Genetic-guided Risk Assessment and Management of Thyroid Cancer

Endocrinol Metab Clin North Am. 2019 Mar;48(1):109-124. doi: 10.1016/j.ecl.2018.11.007.

Author

Mingzhao Xing¹

Affiliation

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA. Electronic address: mxing1@jhmi.edu.

Abstract

Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

Keywords: BRAF V600E mutation; Genetic molecular marker; Prognosis; RAS mutation; Risk stratification; TERT promoter Mutation; Thyroid cancer.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Biomarkers, Tumor*
Humans
Risk Assessment*
Thyroid Neoplasms / diagnosis*
Thyroid Neoplasms / genetics*

Substances

Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding